Navigation Links
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
Date:7/23/2013

equency of adverse events was lower in the ARRY-502 group including fewer asthma exacerbations versus the placebo group.  There were no treatment-emergent serious adverse events in patients receiving ARRY-502; all treatment-related adverse events were either mild or moderate in severity.  A total of 15 (11 in the placebo group, 4 in the ARRY-502 group) out of 184 patients discontinued the study early, primarily due to exacerbations of asthma (5 in the placebo group, 1 in the ARRY-502 group).

"There remains a significant need for more convenient, safe and effective therapies for patients with persistent allergic asthma," said Sally Wenzel M.D., Professor of Medicine and Director of the Asthma Institute at the University of Pittsburgh and lead investigator of this trial.
"ARRY-502 is the first oral non-steroidal drug since Singulair® (montelukast) to demonstrate clinically meaningful activity in allergic asthma and represents a potential new oral therapy that may meet these needs."

Ron Squarer, Chief Executive Officer of Array, noted, "With many asthma patients poorly controlled on currently available therapies, a drug targeting a novel, non-overlapping mechanism may present an important new option for millions of patients.  We are seeking an appropriate partner to develop ARRY-502 to its full potential." 

Conference Call InformationArray will hold a conference call on Tuesday, July 23, 2013, at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer, will lead the call.Conference Call InformationDate:Tuesday, July 23, 2013Time:9:00 a.m. eastern timeToll-Free:(888) 771-4371Toll:(847) 585-4405Pass Code:35320183Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout ARRY-502 and CRTh2A
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. Enterprise Europe Network - Sport Meets Business: How Entrepreneurs Beat the Recession
3. Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
4. Omnetics Meets Increasing Demands of Miniature Electronics Industry with Custom Designed Micro and Nano Cables
5. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
6. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
7. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
8. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
9. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
10. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
11. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)...   Hospira, Inc. (NYSE: HSP ... infusion technologies, today announced that the company will present ... Wednesday, Jan. 14, 2015, in San Francisco.  ... 10:30 a.m. Pacific time on Wednesday, Jan. 14, 2015.  ... a live audiocast accessible via the Investor Relations section ...
(Date:12/19/2014)... 19, 2014 In today,s rapidly changing, ... communication tools are essential for survival. The world ... consumers, desires, preferences, and unmet needs are evolving ... groups across all industries are continually searching for ... the adoption of new market research techniques like ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... of Sustainable, Organic Livestock and ... ... Neptune Industries,Inc. (OTC Bulletin Board: NPDI), a next generation aquaculture technology,company ... production, and related,natural and organic food products, announced today that Phase ...
... Open Label Trial Published in Online Edition ... of ... reduced hemolysis and improved fatigue, overall,quality of life and anemia in ... nocturnal hemoglobinuria (PNH), according,to an analysis of the Phase III SHEPHERD ...
Cached Medicine Technology:Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 2Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 3Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 4Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 2Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 3Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 4Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 5Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 6Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 7
(Date:12/22/2014)... NAPW honors Cheryl ... the Year. She is recognized with this prestigious distinction ... networking organization of professional women in the country, spanning ... Professional Women is a vibrant networking community with over ... Kreider is passionate and committed to best practices that ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/22/2014)... 2014 Parker & Sons, Inc. a ... Arizona home contracting services reports a record number of ... services in 2014. As a company that has served ... Parker and Sons is a business that is focused ... side-by-side with other top quality companies in Arizona that ...
(Date:12/21/2014)... BambooFlooringChina.com, a famous bamboo lumber supplier, has announced ... launched a bamboo flooring promotion with great discounts, up ... 2015. , According to the CEO of the business, ... today; it has a highly distinctive grain with a ... bamboo is made by a unique manufacturing process which ...
(Date:12/21/2014)... 2014 BellasDress.com offers a wide range ... Today, it announces its BellasDress Christmas Sale , ... online store. , BellasDress is a famous online supplier ... fans through a series of promotions. The dress experts ... , “We are proud of offering high quality ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... and sanitation severely limited in Lebanon due to Israeli ... for a coordinated, regional response to the crisis. // ... patients with chronic conditions is a major concern," according ... Israel retaliated to the cross border Hizbollah attacks on ...
... today said it will issue 20 lakh equity shares to ... // ,The board of directors has approved the ... a price of Rs 100 on a preferential basis to ... Stock Exchange., ,The board also approved the allotment of ...
... Health experts have warned that many of the youths ... may undergo premature ageing.// ,The experts explained ... toll on the health of the youth. Dr Lim ... disorders unit, Singapore General Hospital, said, "Heavy food during ...
... avert about 5,7-million HIV infections by 2026.// ... of Science Medicine, stated that male circumcision could avert ... over the next decade. ,According to the ... 2,7-million deaths by 2026. Because circumcision reduces male vulnerability ...
... be vigilant about meningococcal disease after a two-year-old boy died ... on Saturday with fever-like symptoms, but was sent to the ... emergency department. Queensland Health spokesman Dr Jeffrey Hanna said that ... shifted to the hospital. ,"The question for us ...
... ablation and radiation therapy, when used to treat patients ... cancer, increases chances of survival//, say researchers ... study looking at patients over seven years, the median ... after radiation alone to 42 months when thermal ablation ...
Cached Medicine News:Health News:Circumcision to Avert HIV Infection 2Health News:Combination Therapy to the Rescue off Lung Cancer Patients 2Health News:Combination Therapy to the Rescue off Lung Cancer Patients 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: